NRX Pharmaceuticals (NRXP) Operating Expenses (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Operating Expenses data on file, last reported at $5.8 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 51.03% year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $19.4 million, a 18.73% increase from a year earlier, with the FY2025 full-year figure at $17.4 million, down 5.69% from the prior year.
• Operating Expenses for Q1 2026 stood at $5.8 million, up from $5.6 million in the prior quarter.
• Over the last five years, Operating Expenses for NRXP reached as high as $15.7 million in Q1 2022 and fell as low as $2.4 million in Q4 2024.
• Historically, Operating Expenses has averaged $6.4 million across 5 years, with a median of $5.8 million in 2023.
• Across the five-year window, Operating Expenses tumbled 81.33% in 2022 and soared 130.55% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $9.9 million in 2022, then slumped by 55.44% to $4.4 million in 2023, then sank by 44.8% to $2.4 million in 2024, then surged by 130.55% to $5.6 million in 2025, then gained by 3.62% to $5.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $5.8 million in Q1 2026, $5.6 million in Q4 2025, and $4.3 million in Q3 2025.